Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KILT: lacutamab + GEMOX versus GEMOX in relapsed/refractory peripheral T-cell lymphoma
2024-513252-15-00Phase 2Completed
- Sponsor
- LYSARC
- Start
- Jan 2021
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 4
01
Overview
Phase 2, randomised, open-label trial of lacutamab, gemcitabine and oxaliplatin in peripheral T-cell lymphoma (PTCL) (2 arms), sponsored by LYSARC. Primary endpoint: modified progression-free survival. Started Jan 2021; status: completed.
02
Drugs
lacutamabgemcitabineoxaliplatin
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on 2024-513252-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513252-15-00.